• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RLX

    RLX Technology Inc.

    Subscribe to $RLX
    $RLX
    Medicinal Chemicals and Botanical Products
    Health Care

    RLX Technology Inc., together with its subsidiaries, researchers, develops, manufactures, distributes, and sells e-vapor products in the People's Republic of China. It serves RELX branded partner stores and other retail outlets through distributors. RLX Technology Inc. was founded in 2018 and is based in Beijing, China.

    IPO Year: 2021

    Exchange: NYSE

    Website: https://www.relxtech.com

    Recent Analyst Ratings for RLX Technology Inc.

    DatePrice TargetRatingAnalyst
    3/17/2025$2.80 → $2.50Buy → Neutral
    Citigroup
    8/8/2023$2.60Buy
    UBS
    See more ratings

    RLX Technology Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Files 2024 Annual Report on Form 20-F

      SHENZHEN, China, April 17, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the U.S. Securities and Exchange Commission (the "SEC") on April 17, 2025. The annual report on Form 20-F can be accessed on the SEC's website at https://www.sec.gov and on the Company's investor relations website at https://ir.relxtech.com. The Company will provide a hard copy of its audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. About RLX Technology Inc. RLX Techno

      4/17/25 8:00:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 14, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on March 14, 2025 - SHENZHEN, China, March 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before the U.S. markets open on Friday, March 14, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 14, 2025 (8:00 PM Beijing/Hong Kong Time on March 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412

      3/3/25 10:30:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology's MSCI ESG Rating Upgraded to "AA", Achieving the Highest Rating in the Global Tobacco Industry

      SHENZHEN, China, Dec. 30, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, has recently achieved an "AA" rating in the MSCI ESG rating, upgraded from an "A" rating. RLX Technology has secured the top position in the global e-cigarette industry for three consecutive years and has achieved the highest MSCI ESG rating in the global tobacco industry. MSCI ESG ratings aim to measure a company's management of financially relevant ESG risks and opportunities and rate over 8,500 companies every year. MSC

      12/30/24 4:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Third Quarter 2024 Financial Results

      SHENZHEN, China, Nov. 15, 2024 /PRNEWSWIRE/ - RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Net revenues were RMB756.3 million (US$107.8 million) in the third quarter of 2024, compared with RMB498.9 million in the same period of 2023.Gross margin was 27.2% in the third quarter of 2024, compared with 24.1% in the same period of 2023.U.S. GAAP net income was RMB169.4 million (US$24.1 million) in the third quarter of 2024, compared with RMB176.6 million in the same period of 2023.Non-GAAP net inco

      11/15/24 4:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Third Quarter 2024 Financial Results on November 15, 2024

      - Earnings Call Scheduled for 7:00 a.m. ET on November 15, 2024 - SHENZHEN, China, Nov. 5, 2024  /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for third quarter ended September 30, 2024, before the U.S. markets open on Friday, November 15, 2024. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 15, 2024 (8:00 PM Beijing/Hong Kong Time on November 15, 2024). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-606

      11/5/24 2:00:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Second Quarter 2024 Financial Results

      SHENZHEN, China, Aug. 16, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Net revenues were RMB627.2 million (US$86.3 million) in the second quarter of 2024, compared with RMB378.1 million in the same period of 2023.Gross margin was 25.2% in the second quarter of 2024, compared with 26.1% in the same period of 2023.U.S. GAAP net income was RMB134.9 million (US$18.6 million) in the second quarter of 2024, compared with RMB204.7 million in the same period of 2023.Non-GAAP net inco

      8/16/24 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Second Quarter 2024 Financial Results on August 16, 2024

      - Earnings Call Scheduled for 8:00 a.m. ET on August 16, 2024 – SHENZHEN, China, Aug. 6, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for second quarter ended June 30, 2024, before the U.S. markets open on Friday, August 16, 2024. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 16, 2024 (8:00 PM Beijing/Hong Kong Time on August 16, 2024). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong,

      8/6/24 5:00:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited First Quarter 2024 Financial Results

      SHENZHEN, China, May 17, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Net revenues were RMB551.6 million (US$76.4 million) in the first quarter of 2024, compared with RMB188.9 million in the same period of 2023.Gross margin was 25.9% in the first quarter of 2024, compared with 24.2% in the same period of 2023.U.S. GAAP net income was RMB132.6 million (US$18.4 million) in the first quarter of 2024, compared with U.S. GAAP net loss of RMB56.3 million in the same period of 2023.N

      5/17/24 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    RLX Technology Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RLX Technology downgraded by Citigroup with a new price target

      Citigroup downgraded RLX Technology from Buy to Neutral and set a new price target of $2.50 from $2.80 previously

      3/17/25 7:42:34 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • UBS initiated coverage on RLX Technology with a new price target

      UBS initiated coverage of RLX Technology with a rating of Buy and set a new price target of $2.60

      8/8/23 9:12:45 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    RLX Technology Inc. Financials

    Live finance-specific insights

    See more
    • RLX Technology to Report First Quarter 2025 Financial Results on May 16, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on May 16, 2025 - SHENZHEN, China, May 8, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2025, before the U.S. markets open on Friday, May 16, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 16, 2025 (8:00 PM Beijing/Hong Kong Time on May 16, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (to

      5/8/25 2:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2024 Financial Results

      SHENZHEN, China, March 14, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Net revenues were RMB813.5 million (US$111.4 million) in the fourth quarter of 2024, compared with RMB520.5 million in the same period of 2023.Gross margin was 27.0% in the fourth quarter of 2024, compared with 23.7% in the same period of 2023.U.S. GAAP net income was RMB127.4 million (US$17.5 million) in the fourth quarter of 2024, compared with RMB216.0 million in the same period

      3/14/25 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Fourth Quarter and Fiscal Year 2024 Financial Results on March 14, 2025

      - Earnings Call Scheduled for 8:00 a.m. ET on March 14, 2025 - SHENZHEN, China, March 3, 2025 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2024, before the U.S. markets open on Friday, March 14, 2025. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on March 14, 2025 (8:00 PM Beijing/Hong Kong Time on March 14, 2025). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412

      3/3/25 10:30:00 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Third Quarter 2024 Financial Results

      SHENZHEN, China, Nov. 15, 2024 /PRNEWSWIRE/ - RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights Net revenues were RMB756.3 million (US$107.8 million) in the third quarter of 2024, compared with RMB498.9 million in the same period of 2023.Gross margin was 27.2% in the third quarter of 2024, compared with 24.1% in the same period of 2023.U.S. GAAP net income was RMB169.4 million (US$24.1 million) in the third quarter of 2024, compared with RMB176.6 million in the same period of 2023.Non-GAAP net inco

      11/15/24 4:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Third Quarter 2024 Financial Results on November 15, 2024

      - Earnings Call Scheduled for 7:00 a.m. ET on November 15, 2024 - SHENZHEN, China, Nov. 5, 2024  /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for third quarter ended September 30, 2024, before the U.S. markets open on Friday, November 15, 2024. The Company's management will host an earnings conference call at 7:00 AM U.S. Eastern Time on November 15, 2024 (8:00 PM Beijing/Hong Kong Time on November 15, 2024). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-606

      11/5/24 2:00:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Second Quarter 2024 Financial Results

      SHENZHEN, China, Aug. 16, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights Net revenues were RMB627.2 million (US$86.3 million) in the second quarter of 2024, compared with RMB378.1 million in the same period of 2023.Gross margin was 25.2% in the second quarter of 2024, compared with 26.1% in the same period of 2023.U.S. GAAP net income was RMB134.9 million (US$18.6 million) in the second quarter of 2024, compared with RMB204.7 million in the same period of 2023.Non-GAAP net inco

      8/16/24 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report Second Quarter 2024 Financial Results on August 16, 2024

      - Earnings Call Scheduled for 8:00 a.m. ET on August 16, 2024 – SHENZHEN, China, Aug. 6, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for second quarter ended June 30, 2024, before the U.S. markets open on Friday, August 16, 2024. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 16, 2024 (8:00 PM Beijing/Hong Kong Time on August 16, 2024). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong,

      8/6/24 5:00:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited First Quarter 2024 Financial Results

      SHENZHEN, China, May 17, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Net revenues were RMB551.6 million (US$76.4 million) in the first quarter of 2024, compared with RMB188.9 million in the same period of 2023.Gross margin was 25.9% in the first quarter of 2024, compared with 24.2% in the same period of 2023.U.S. GAAP net income was RMB132.6 million (US$18.4 million) in the first quarter of 2024, compared with U.S. GAAP net loss of RMB56.3 million in the same period of 2023.N

      5/17/24 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology to Report First Quarter 2024 Financial Results on May 17, 2024

      - Earnings Call Scheduled for 8:00 a.m. ET on May 17, 2024 – SHENZHEN, China, May 7, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced that it will report its unaudited financial results for first quarter ended March 31, 2024, before the U.S. markets open on Friday, May 17, 2024. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 17, 2024 (8:00 PM Beijing/Hong Kong Time on May 17, 2024). Dial-in details for the earnings conference call are as follows: United States (toll free): +1-888-317-6003 International: +1-412-317-6061 Hong Kong, China (toll f

      5/7/24 5:00:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • RLX Technology Announces Unaudited Fourth Quarter and Fiscal Year 2023 Financial Results

      SHENZHEN, China, March 15, 2024 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE:RLX), a leading global branded e-vapor company, today announced its unaudited financial results for the fourth quarter and the fiscal year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights Net revenues were RMB520.5 million (US$73.3 million) in the fourth quarter of 2023, compared with RMB340.0 million in the same period of 2022.Gross margin was 23.7% in the fourth quarter of 2023, compared with 43.6% in the same period of 2022.U.S. GAAP net income was RMB216.0 million (US$30.4 million) in the fourth quarter of 2023, compared with U.S. GAAP net loss of RMB225.1 milli

      3/15/24 5:30:00 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    RLX Technology Inc. SEC Filings

    See more
    • SEC Form 20-F filed by RLX Technology Inc.

      20-F - RLX Technology Inc. (0001828365) (Filer)

      4/17/25 4:01:47 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      3/14/25 6:10:16 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      11/15/24 4:01:25 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      8/16/24 6:20:05 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      5/17/24 6:02:27 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      4/19/24 4:04:51 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 20-F filed by RLX Technology Inc.

      20-F - RLX Technology Inc. (0001828365) (Filer)

      4/19/24 4:02:35 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      3/21/24 7:57:28 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      12/29/23 6:04:12 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by RLX Technology Inc.

      6-K - RLX Technology Inc. (0001828365) (Filer)

      12/5/23 6:43:42 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care

    RLX Technology Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/7/24 6:06:29 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/6/24 4:01:28 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/14/23 6:01:42 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by RLX Technology Inc. (Amendment)

      SC 13G/A - RLX Technology Inc. (0001828365) (Subject)

      2/13/23 4:01:25 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by RLX Technology Inc.

      SC 13G - RLX Technology Inc. (0001828365) (Subject)

      3/29/22 8:51:15 AM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by RLX Technology Inc.

      SC 13G - RLX Technology Inc. (0001828365) (Subject)

      2/11/22 4:01:22 PM ET
      $RLX
      Medicinal Chemicals and Botanical Products
      Health Care